Evidence map›Paper›PMID 31689961›Full record

ReviewInternational journal of molecular sciences2019

The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.

Mitsuhiro Nakamura, Takeshi Obata, Takiko Daikoku, Hiroshi Fujiwara

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The role and mechanism of human papillomavirus in urinary system tumors.The Journal of international medical research · 2025
    Review
  14. Article
  15. Deciphering the Expression, Functional Role, and Prognostic Significance ofJournal of obstetrics and gynaecology of India · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mitsuhiro NakamuraDepartment of Obstetrics and Gynecology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Japan. mitsu222@med.kanazawa-u.ac.jp.
Takeshi ObataDepartment of Obstetrics and Gynecology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Japan. t-oba.0919@hotmail.co.jp.
Takiko DaikokuInstitute for Experimental Animals, Kanazawa University Advanced Science Research Center, Kanazawa University, Kanazawa 920-8641, Japan. tdaikoku@kiea.m.kanazawa-u.ac.jp.
Hiroshi FujiwaraDepartment of Obstetrics and Gynecology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Japan. fuji@kuhp.kyoto-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysfunction of p53 is observed in the many malignant tumors. In cervical cancer, p53 is inactivated by degradation through the complex with human papilloma virus (HPV) oncoprotein E6 and E6-associated protein (E6AP), an E3 ubiquitin protein ligase. In endometrial cancer, overexpression of p53 in immunohistochemistry is a significant prognostic factor. A discrepancy between p53 overexpression and TP53 mutations is observed in endometrioid endometrial cancer, indicating that the accumulation of p53 protein can be explained by not only gene mutations but also dysregulation of the factors such as ERβ and MDM2. Furthermore, the double-positive expression of immunoreactive estrogen receptor (ER) β and p53 proteins is closely associated with the incidence of metastasis and/or recurrence. High-grade serous ovarian carcinoma (HGSC) arises from secretary cells in the fallopian tube. The secretary cell outgrowth (SCOUT) with TP53 mutations progresses to HGSC via the p53 signature, serous intraepithelial lesion (STIL), and serous intraepithelial carcinoma (STIC), indicating that TP53 mutation is associated with carcinogenesis of HGSC. Clinical application targeting p53 has been approved for some malignant tumors. Gene therapy by the adenovirus-mediated p53 gene transfer system is performed for head and neck cancer. A clinical phase III trial using MDM2/X inhibitors, idasanutlin (RG7388) combined with cytarabine, is being performed involving relapse/refractory acute myeloid leukemia patients. The use of adenoviruses as live vectors which encode wild-type p53 has given promising results in cervical cancer patients.

Indexed as

Biomarkers, TumorCarcinomaFemaleGenetic TherapyHumansOvarian NeoplasmsTumor Suppressor Protein p53Uterine NeoplasmsBiomarkers, TumorTumor Suppressor Protein p53cervical cancerendometrial cancergene therapyHPVovarian cancerp53 overexpressionp53 signatureSTICTP53 mutation

Identifiers

PMID31689961
PMCPMC6862296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.